m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00215)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
CEBPA
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by FTO | ||
Cell Line | NB4 cell line | Homo sapiens |
Treatment: shFTO NB4 cells
Control: shNS NB4 cells
|
GSE103494 | |
Regulation |
|
logFC: 6.07E-01 p-value: 3.92E-03 |
More Results | Click to View More RNA-seq Results |
In total 2 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CCAAT/enhancer-binding protein alpha (CEBPA) signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Glioma | ICD-11: 2A00.0 | ||
Responsed Drug | R-2HG | Investigative | ||
Cell Process | Glutamine metabolism | |||
Cell apoptosis | ||||
In-vitro Model | 8-MG-BA | Glioblastoma | Homo sapiens | CVCL_1052 |
A-172 | Glioblastoma | Homo sapiens | CVCL_0131 | |
DK-MG | Glioblastoma | Homo sapiens | CVCL_1173 | |
GaMG | Glioblastoma | Homo sapiens | CVCL_1226 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
Jurkat | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0065 | |
KOCL-45 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3993 | |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
KOCL-50 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6866 | |
KOCL-51 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6865 | |
KOCL-69 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3995 | |
KOPN-1 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3937 | |
LN-18 | Glioblastoma | Homo sapiens | CVCL_0392 | |
LN-229 | Glioblastoma | Homo sapiens | CVCL_0393 | |
MA9.3 (MA9.3) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
MA9.6 (MLL-AF9) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
ME-1 [Human leukemia] | Adult acute myeloid leukemia | Homo sapiens | CVCL_2110 | |
ML-2 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1418 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
NOMO-1 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1609 | |
PL21 | Familial adenomatous polyposis | Homo sapiens | CVCL_JM48 | |
T98G | Glioblastoma | Homo sapiens | CVCL_0556 | |
THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 | |
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
U-937 | Adult acute monocytic leukemia | Homo sapiens | CVCL_0007 | |
In-vivo Model | For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation. | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CCAAT/enhancer-binding protein alpha (CEBPA) signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Leukaemia | ICD-11: 2B33.4 | ||
Responsed Drug | R-2HG | Investigative | ||
Cell Process | Glutamine metabolism | |||
Cell apoptosis | ||||
In-vitro Model | 8-MG-BA | Glioblastoma | Homo sapiens | CVCL_1052 |
A-172 | Glioblastoma | Homo sapiens | CVCL_0131 | |
DK-MG | Glioblastoma | Homo sapiens | CVCL_1173 | |
GaMG | Glioblastoma | Homo sapiens | CVCL_1226 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
Jurkat | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0065 | |
KOCL-45 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3993 | |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
KOCL-50 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6866 | |
KOCL-51 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6865 | |
KOCL-69 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3995 | |
KOPN-1 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3937 | |
LN-18 | Glioblastoma | Homo sapiens | CVCL_0392 | |
LN-229 | Glioblastoma | Homo sapiens | CVCL_0393 | |
MA9.3 (MA9.3) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
MA9.6 (MLL-AF9) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
ME-1 [Human leukemia] | Adult acute myeloid leukemia | Homo sapiens | CVCL_2110 | |
ML-2 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1418 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
NOMO-1 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1609 | |
PL21 | Familial adenomatous polyposis | Homo sapiens | CVCL_JM48 | |
T98G | Glioblastoma | Homo sapiens | CVCL_0556 | |
THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 | |
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
U-937 | Adult acute monocytic leukemia | Homo sapiens | CVCL_0007 | |
In-vivo Model | For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation. | |||
Brain cancer [ICD-11: 2A00]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CCAAT/enhancer-binding protein alpha (CEBPA) signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. | |||
Responsed Disease | Glioma [ICD-11: 2A00.0] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Responsed Drug | R-2HG | Investigative | ||
Cell Process | Glutamine metabolism | |||
Cell apoptosis | ||||
In-vitro Model | 8-MG-BA | Glioblastoma | Homo sapiens | CVCL_1052 |
A-172 | Glioblastoma | Homo sapiens | CVCL_0131 | |
DK-MG | Glioblastoma | Homo sapiens | CVCL_1173 | |
GaMG | Glioblastoma | Homo sapiens | CVCL_1226 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
Jurkat | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0065 | |
KOCL-45 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3993 | |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
KOCL-50 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6866 | |
KOCL-51 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6865 | |
KOCL-69 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3995 | |
KOPN-1 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3937 | |
LN-18 | Glioblastoma | Homo sapiens | CVCL_0392 | |
LN-229 | Glioblastoma | Homo sapiens | CVCL_0393 | |
MA9.3 (MA9.3) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
MA9.6 (MLL-AF9) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
ME-1 [Human leukemia] | Adult acute myeloid leukemia | Homo sapiens | CVCL_2110 | |
ML-2 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1418 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
NOMO-1 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1609 | |
PL21 | Familial adenomatous polyposis | Homo sapiens | CVCL_JM48 | |
T98G | Glioblastoma | Homo sapiens | CVCL_0556 | |
THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 | |
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
U-937 | Adult acute monocytic leukemia | Homo sapiens | CVCL_0007 | |
In-vivo Model | For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation. | |||
Malignant haematopoietic neoplasm [ICD-11: 2B33]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CCAAT/enhancer-binding protein alpha (CEBPA) signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. | |||
Responsed Disease | Leukaemia [ICD-11: 2B33.4] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Responsed Drug | R-2HG | Investigative | ||
Cell Process | Glutamine metabolism | |||
Cell apoptosis | ||||
In-vitro Model | 8-MG-BA | Glioblastoma | Homo sapiens | CVCL_1052 |
A-172 | Glioblastoma | Homo sapiens | CVCL_0131 | |
DK-MG | Glioblastoma | Homo sapiens | CVCL_1173 | |
GaMG | Glioblastoma | Homo sapiens | CVCL_1226 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
Jurkat | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0065 | |
KOCL-45 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3993 | |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
KOCL-50 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6866 | |
KOCL-51 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6865 | |
KOCL-69 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3995 | |
KOPN-1 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3937 | |
LN-18 | Glioblastoma | Homo sapiens | CVCL_0392 | |
LN-229 | Glioblastoma | Homo sapiens | CVCL_0393 | |
MA9.3 (MA9.3) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
MA9.6 (MLL-AF9) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
ME-1 [Human leukemia] | Adult acute myeloid leukemia | Homo sapiens | CVCL_2110 | |
ML-2 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1418 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
NOMO-1 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1609 | |
PL21 | Familial adenomatous polyposis | Homo sapiens | CVCL_JM48 | |
T98G | Glioblastoma | Homo sapiens | CVCL_0556 | |
THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 | |
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
U-937 | Adult acute monocytic leukemia | Homo sapiens | CVCL_0007 | |
In-vivo Model | For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation. | |||
R-2HG
[Investigative]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CCAAT/enhancer-binding protein alpha (CEBPA) signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Glioma | ICD-11: 2A00.0 | ||
Cell Process | Glutamine metabolism | |||
Cell apoptosis | ||||
In-vitro Model | 8-MG-BA | Glioblastoma | Homo sapiens | CVCL_1052 |
A-172 | Glioblastoma | Homo sapiens | CVCL_0131 | |
DK-MG | Glioblastoma | Homo sapiens | CVCL_1173 | |
GaMG | Glioblastoma | Homo sapiens | CVCL_1226 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
Jurkat | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0065 | |
KOCL-45 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3993 | |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
KOCL-50 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6866 | |
KOCL-51 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6865 | |
KOCL-69 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3995 | |
KOPN-1 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3937 | |
LN-18 | Glioblastoma | Homo sapiens | CVCL_0392 | |
LN-229 | Glioblastoma | Homo sapiens | CVCL_0393 | |
MA9.3 (MA9.3) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
MA9.6 (MLL-AF9) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
ME-1 [Human leukemia] | Adult acute myeloid leukemia | Homo sapiens | CVCL_2110 | |
ML-2 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1418 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
NOMO-1 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1609 | |
PL21 | Familial adenomatous polyposis | Homo sapiens | CVCL_JM48 | |
T98G | Glioblastoma | Homo sapiens | CVCL_0556 | |
THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 | |
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
U-937 | Adult acute monocytic leukemia | Homo sapiens | CVCL_0007 | |
In-vivo Model | For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation. | |||
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CCAAT/enhancer-binding protein alpha (CEBPA) signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Leukaemia | ICD-11: 2B33.4 | ||
Cell Process | Glutamine metabolism | |||
Cell apoptosis | ||||
In-vitro Model | 8-MG-BA | Glioblastoma | Homo sapiens | CVCL_1052 |
A-172 | Glioblastoma | Homo sapiens | CVCL_0131 | |
DK-MG | Glioblastoma | Homo sapiens | CVCL_1173 | |
GaMG | Glioblastoma | Homo sapiens | CVCL_1226 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
Jurkat | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0065 | |
KOCL-45 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3993 | |
KOCL-48 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_6867 | |
KOCL-50 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6866 | |
KOCL-51 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_6865 | |
KOCL-69 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3995 | |
KOPN-1 | B acute lymphoblastic leukemia | Homo sapiens | CVCL_3937 | |
LN-18 | Glioblastoma | Homo sapiens | CVCL_0392 | |
LN-229 | Glioblastoma | Homo sapiens | CVCL_0393 | |
MA9.3 (MA9.3) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
MA9.6 (MLL-AF9) | ||||
MA9.6ITD (MLL-AF9 plus FLT3-ITD) | ||||
MA9.6RAS (MLL-AF9 plus NRasG12D) | ||||
ME-1 [Human leukemia] | Adult acute myeloid leukemia | Homo sapiens | CVCL_2110 | |
ML-2 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1418 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
NOMO-1 | Adult acute monocytic leukemia | Homo sapiens | CVCL_1609 | |
PL21 | Familial adenomatous polyposis | Homo sapiens | CVCL_JM48 | |
T98G | Glioblastoma | Homo sapiens | CVCL_0556 | |
THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 | |
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
U-937 | Adult acute monocytic leukemia | Homo sapiens | CVCL_0007 | |
In-vivo Model | For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation. | |||